Lillys triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications

▤ Summary

Eli Lilly announced positive Phase 3 results for retatrutide, its investigational triple agonist for obesity, type 2 diabetes, and related conditions. The trial data showed major weight loss, large A1C reductions, and improvements in knee osteoarthritis pain and obstructive sleep apnea. Lilly also reported favorable changes in several cardiovascular risk factors, while adverse events remained broadly consistent with other incretin therapies. The company said it is continuing its late-stage clinical program and expects more readouts over the next year.

▦ Linked Companies